LEO Pharma

137 articles about LEO Pharma

• LEO Pharma Announces More Than Half Of Patients On Kyntheum (Brodalumab) Maintain Consistent Levels Of Complete Skin Clearance For More Than Two Years

  9/14/2017

• China's HitGen To Discover Lead Molecules For LEO Pharma Of Denmark

  8/8/2017

• HitGen And LEO Pharma Enter Research Collaboration

  8/7/2017

• LEO Pharma Receives Marketing Authorisation For Kyntheum (Brodalumab), A New Biologic For The Treatment Of Moderate-To-Severe Plaque Psoriasis In The European Union

  7/20/2017

• LEO Pharma Appoints Chris Posner To Lead US Business

  6/23/2017

• Argenx Receives Second Preclinical Milestone Payment In Collaboration With LEO Pharma

  6/20/2017

• LEO Pharma Starts Phase III Clinical Study For Tralokinumab In Atopic Dermatitis

  6/15/2017

• Almirall And LEO Pharma Join Forces To Advance Dermatology Research By Setting A New Standard

  5/31/2017

• LEO Pharma U.S. Welcomes Judit H. Nyirady As Vice President Of Medical Strategy & Scientific Affairs

  5/4/2017

• Klox Technologies And LEO Pharma Set Up Company For Biophotonic In Dermatology

  3/6/2017

• LEO Pharma Announces Positive Results From Phase 2b Clinical Study For Tralokinumab In Atopic Dermatitis

  3/3/2017

• MorphoSys AG And LEO Pharma Enter Into Strategic Alliance To Develop Therapeutic Antibodies In Dermatology

  11/2/2016

• Denmark's LEO Pharma Opens Up Shop in Cambridge

  9/30/2016

• AstraZeneca PLC, Valeant and LEO Pharma Shuffle Dermatology Rights, Potential $1 Billion in Sales at Stake

  7/5/2016

• LEO Pharma to Pay AstraZeneca PLC $115 Million Upfront and $1 Billion in Milestones for Two Dermatology Drug Rights

  7/1/2016

• American Skin Association Announces New Board Of Directors Members Gitte Aabo Of LEO Pharma And Dr. George Cotsarelis Of Penn Medicine

  4/25/2016

• LEO Pharma Receives Scientific Approval Of Enstilar For The Treatment Of Psoriasis In EU

  3/21/2016

• arGEN-X Receives Milestone Payment In LEO Pharma Collaboration

  2/2/2016

• LEO Pharma Puts Up €675 Million for Astellas's Global Dermatology Biz

  11/11/2015

• LEO Pharma Announces FDA Approval Of Enstilar(Calcipotriene And Betamethasone Dipropionate) Foam, 0.005%/0.064% For Plaque Psoriasis

  10/19/2015